Home — Centre for Medicines Discovery (CMD)

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

News

Diagram showing how genetic instability in normal cells leads to tumour formation through acquired mutations. It illustrates two outcomes: mutations activating cancer-driving pathways, and cancer cells becoming dependent on specific signalling pathways, both of which can be targeted by precision medicines.

Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment

31 March 2026

Schematic showing how the CBH-002 probe detects different types of PRMT5 inhibitors and senses changes in cellular metabolic state of SAM. Credit: Rothweiler et al., Nat Comm 2025

Oxford researchers develop first live-cell assay linking cancer tumour metabolism to drug effectiveness

9 December 2025

Discovery reveals 'handbrake' that controls cancer drug response

10 November 2025

CMD drives public engagement success at the GreenMan Festival 2025

19 September 2025

More news

Publications

Symptom Duration-Dependent Protein Abundance Changes in Symptomatic and Asymptomatic Tendons in Early Stage Unilateral Patellar Tendinopathy.

Steffen D. et al, (2026), J Proteome Res, 25, 2170 - 2182

Proteomic Snapshots of Structural Cross-Linking Rearrangements in Ca2+/Calmodulin-Dependent Kinase-1-Delta Associated with Its Regulation by ATP, Ca2+/Calmodulin, and Reduction Potential.

Mbabala L. et al, (2026), J Proteome Res, 25, 1914 - 1928

Rational discovery of therapeutic PAK1 allosteric activators.

He Y. et al, (2026), Cell